全身性特発性若年性関節炎治療の世界市場（～2026年）

• 英文タイトル：Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY04784 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は全身性特発性若年性関節炎治療のグローバル市場について調査・分析したレポートです。種類別（アダリムマブバイオシミラー、カナキヌマブ、ゴリムマブ、トシリズマブバイオシミラー、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別全身性特発性若年性関節炎治療の競争状況、市場シェア ・世界の全身性特発性若年性関節炎治療市場：種類別市場規模 2015年-2020年（アダリムマブバイオシミラー、カナキヌマブ、ゴリムマブ、トシリズマブバイオシミラー、その他） ・世界の全身性特発性若年性関節炎治療市場：種類別市場規模予測 2021年-2026年（アダリムマブバイオシミラー、カナキヌマブ、ゴリムマブ、トシリズマブバイオシミラー、その他） ・世界の全身性特発性若年性関節炎治療市場：用途別市場規模 2015年-2020年（クリニック、病院、その他） ・世界の全身性特発性若年性関節炎治療市場：用途別市場規模予測 2021年-2026年（クリニック、病院、その他） ・北米の全身性特発性若年性関節炎治療市場分析：米国、カナダ ・ヨーロッパの全身性特発性若年性関節炎治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの全身性特発性若年性関節炎治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の全身性特発性若年性関節炎治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの全身性特発性若年性関節炎治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Alteogen Inc.、Bristol-Myers Squibb Company、Epirus Biopharmaceuticals, Inc.、Johnson & Johnson、Momenta Pharmaceuticals, Inc.、Mycenax Biotech Inc.、Novartis AG、Oncobiologics, Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Systemic Idiopathic Juvenile Arthritis Treatment Market
The global Systemic Idiopathic Juvenile Arthritis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Systemic Idiopathic Juvenile Arthritis Treatment Scope and Market Size
Systemic Idiopathic Juvenile Arthritis Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Systemic Idiopathic Juvenile Arthritis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Alteogen Inc.
Bristol-Myers Squibb Company
Epirus Biopharmaceuticals, Inc.
Johnson & Johnson
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Novartis AG
Oncobiologics, Inc.

Market segment by Type, the product can be split into
Adalimumab Biosimilar
Canakinumab
Golimumab
Tocilizumab Biosimilar
Others
Market segment by Application, split into
Clinic
Hospital
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Systemic Idiopathic Juvenile Arthritis Treatment Revenue
1.4 Market by Type
1.4.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Adalimumab Biosimilar
1.4.3 Canakinumab
1.4.4 Golimumab
1.4.5 Tocilizumab Biosimilar
1.4.6 Others
1.5 Market by Application
1.5.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Application: 2020 VS 2026
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Perspective (2015-2026)
2.2 Global Systemic Idiopathic Juvenile Arthritis Treatment Growth Trends by Regions
2.2.1 Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Systemic Idiopathic Juvenile Arthritis Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Systemic Idiopathic Juvenile Arthritis Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Systemic Idiopathic Juvenile Arthritis Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Systemic Idiopathic Juvenile Arthritis Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Systemic Idiopathic Juvenile Arthritis Treatment Players by Market Size
3.1.1 Global Top Systemic Idiopathic Juvenile Arthritis Treatment Players by Revenue (2015-2020)
3.1.2 Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Concentration Ratio
3.2.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Systemic Idiopathic Juvenile Arthritis Treatment Revenue in 2019
3.3 Systemic Idiopathic Juvenile Arthritis Treatment Key Players Head office and Area Served
3.4 Key Players Systemic Idiopathic Juvenile Arthritis Treatment Product Solution and Service
3.5 Date of Enter into Systemic Idiopathic Juvenile Arthritis Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Historic Market Size by Type (2015-2020)
4.2 Global Systemic Idiopathic Juvenile Arthritis Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020)
5.2 Global Systemic Idiopathic Juvenile Arthritis Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Systemic Idiopathic Juvenile Arthritis Treatment Market Size (2015-2020)
6.2 Systemic Idiopathic Juvenile Arthritis Treatment Key Players in North America (2019-2020)
6.3 North America Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020)
6.4 North America Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Size (2015-2020)
7.2 Systemic Idiopathic Juvenile Arthritis Treatment Key Players in Europe (2019-2020)
7.3 Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020)
7.4 Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020)

8 China
8.1 China Systemic Idiopathic Juvenile Arthritis Treatment Market Size (2015-2020)
8.2 Systemic Idiopathic Juvenile Arthritis Treatment Key Players in China (2019-2020)
8.3 China Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020)
8.4 China Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Systemic Idiopathic Juvenile Arthritis Treatment Market Size (2015-2020)
9.2 Systemic Idiopathic Juvenile Arthritis Treatment Key Players in Japan (2019-2020)
9.3 Japan Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020)
9.4 Japan Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Market Size (2015-2020)
10.2 Systemic Idiopathic Juvenile Arthritis Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020)

11 India
11.1 India Systemic Idiopathic Juvenile Arthritis Treatment Market Size (2015-2020)
11.2 Systemic Idiopathic Juvenile Arthritis Treatment Key Players in India (2019-2020)
11.3 India Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020)
11.4 India Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Systemic Idiopathic Juvenile Arthritis Treatment Market Size (2015-2020)
12.2 Systemic Idiopathic Juvenile Arthritis Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020)
12.4 Central & South America Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Alteogen Inc.
13.1.1 Alteogen Inc. Company Details
13.1.2 Alteogen Inc. Business Overview
13.1.3 Alteogen Inc. Systemic Idiopathic Juvenile Arthritis Treatment Introduction
13.1.4 Alteogen Inc. Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020))
13.1.5 Alteogen Inc. Recent Development
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Details
13.2.2 Bristol-Myers Squibb Company Business Overview
13.2.3 Bristol-Myers Squibb Company Systemic Idiopathic Juvenile Arthritis Treatment Introduction
13.2.4 Bristol-Myers Squibb Company Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020)
13.2.5 Bristol-Myers Squibb Company Recent Development
13.3 Epirus Biopharmaceuticals, Inc.
13.3.1 Epirus Biopharmaceuticals, Inc. Company Details
13.3.2 Epirus Biopharmaceuticals, Inc. Business Overview
13.3.3 Epirus Biopharmaceuticals, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Introduction
13.3.4 Epirus Biopharmaceuticals, Inc. Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020)
13.3.5 Epirus Biopharmaceuticals, Inc. Recent Development
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Details
13.4.2 Johnson & Johnson Business Overview
13.4.3 Johnson & Johnson Systemic Idiopathic Juvenile Arthritis Treatment Introduction
13.4.4 Johnson & Johnson Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020)
13.4.5 Johnson & Johnson Recent Development
13.5 Momenta Pharmaceuticals, Inc.
13.5.1 Momenta Pharmaceuticals, Inc. Company Details
13.5.2 Momenta Pharmaceuticals, Inc. Business Overview
13.5.3 Momenta Pharmaceuticals, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Introduction
13.5.4 Momenta Pharmaceuticals, Inc. Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020)
13.5.5 Momenta Pharmaceuticals, Inc. Recent Development
13.6 Mycenax Biotech Inc.
13.6.1 Mycenax Biotech Inc. Company Details
13.6.2 Mycenax Biotech Inc. Business Overview
13.6.3 Mycenax Biotech Inc. Systemic Idiopathic Juvenile Arthritis Treatment Introduction
13.6.4 Mycenax Biotech Inc. Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020)
13.6.5 Mycenax Biotech Inc. Recent Development
13.7 Novartis AG
13.7.1 Novartis AG Company Details
13.7.2 Novartis AG Business Overview
13.7.3 Novartis AG Systemic Idiopathic Juvenile Arthritis Treatment Introduction
13.7.4 Novartis AG Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020)
13.7.5 Novartis AG Recent Development
13.8 Oncobiologics, Inc.
13.8.1 Oncobiologics, Inc. Company Details
13.8.2 Oncobiologics, Inc. Business Overview
13.8.3 Oncobiologics, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Introduction
13.8.4 Oncobiologics, Inc. Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020)
13.8.5 Oncobiologics, Inc. Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Systemic Idiopathic Juvenile Arthritis Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Systemic Idiopathic Juvenile Arthritis Treatment Revenue
Table 3. Ranking of Global Top Systemic Idiopathic Juvenile Arthritis Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Adalimumab Biosimilar
Table 6. Key Players of Canakinumab
Table 7. Key Players of Golimumab
Table 8. Key Players of Tocilizumab Biosimilar
Table 9. Key Players of Others
Table 10. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Regions (2015-2020)
Table 14. Global Systemic Idiopathic Juvenile Arthritis Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Systemic Idiopathic Juvenile Arthritis Treatment Market Growth Strategy
Table 20. Main Points Interviewed from Key Systemic Idiopathic Juvenile Arthritis Treatment Players
Table 21. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Players (2015-2020) (Million US$)
Table 22. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Players (2015-2020)
Table 23. Global Top Systemic Idiopathic Juvenile Arthritis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Systemic Idiopathic Juvenile Arthritis Treatment as of 2019)
Table 24. Global Systemic Idiopathic Juvenile Arthritis Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Systemic Idiopathic Juvenile Arthritis Treatment Product Solution and Service
Table 27. Date of Enter into Systemic Idiopathic Juvenile Arthritis Treatment Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 30. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size Share by Type (2015-2020)
Table 31. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Type (2021-2026)
Table 32. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size Share by Application (2015-2020)
Table 33. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 34. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size Share by Application (2021-2026)
Table 35. North America Key Players Systemic Idiopathic Juvenile Arthritis Treatment Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Systemic Idiopathic Juvenile Arthritis Treatment Market Share (2019-2020)
Table 37. North America Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 38. North America Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Type (2015-2020)
Table 39. North America Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 40. North America Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Application (2015-2020)
Table 41. Europe Key Players Systemic Idiopathic Juvenile Arthritis Treatment Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Systemic Idiopathic Juvenile Arthritis Treatment Market Share (2019-2020)
Table 43. Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Type (2015-2020)
Table 45. Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Application (2015-2020)
Table 47. China Key Players Systemic Idiopathic Juvenile Arthritis Treatment Revenue (2019-2020) (Million US$)
Table 48. China Key Players Systemic Idiopathic Juvenile Arthritis Treatment Market Share (2019-2020)
Table 49. China Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 50. China Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Type (2015-2020)
Table 51. China Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 52. China Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Application (2015-2020)
Table 53. Japan Key Players Systemic Idiopathic Juvenile Arthritis Treatment Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Systemic Idiopathic Juvenile Arthritis Treatment Market Share (2019-2020)
Table 55. Japan Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Type (2015-2020)
Table 57. Japan Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Systemic Idiopathic Juvenile Arthritis Treatment Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Systemic Idiopathic Juvenile Arthritis Treatment Market Share (2019-2020)
Table 61. Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Type (2015-2020)
Table 63. Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Application (2015-2020)
Table 65. India Key Players Systemic Idiopathic Juvenile Arthritis Treatment Revenue (2019-2020) (Million US$)
Table 66. India Key Players Systemic Idiopathic Juvenile Arthritis Treatment Market Share (2019-2020)
Table 67. India Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 68. India Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Type (2015-2020)
Table 69. India Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 70. India Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Systemic Idiopathic Juvenile Arthritis Treatment Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Systemic Idiopathic Juvenile Arthritis Treatment Market Share (2019-2020)
Table 73. Central & South America Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Type (2015-2020)
Table 75. Central & South America Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Application (2015-2020)
Table 77. Alteogen Inc. Company Details
Table 78. Alteogen Inc. Business Overview
Table 79. Alteogen Inc. Product
Table 80. Alteogen Inc. Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020) (Million US$)
Table 81. Alteogen Inc. Recent Development
Table 82. Bristol-Myers Squibb Company Company Details
Table 83. Bristol-Myers Squibb Company Business Overview
Table 84. Bristol-Myers Squibb Company Product
Table 85. Bristol-Myers Squibb Company Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020) (Million US$)
Table 86. Bristol-Myers Squibb Company Recent Development
Table 87. Epirus Biopharmaceuticals, Inc. Company Details
Table 88. Epirus Biopharmaceuticals, Inc. Business Overview
Table 89. Epirus Biopharmaceuticals, Inc. Product
Table 90. Epirus Biopharmaceuticals, Inc. Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020) (Million US$)
Table 91. Epirus Biopharmaceuticals, Inc. Recent Development
Table 92. Johnson & Johnson Company Details
Table 93. Johnson & Johnson Business Overview
Table 94. Johnson & Johnson Product
Table 95. Johnson & Johnson Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020) (Million US$)
Table 96. Johnson & Johnson Recent Development
Table 97. Momenta Pharmaceuticals, Inc. Company Details
Table 98. Momenta Pharmaceuticals, Inc. Business Overview
Table 99. Momenta Pharmaceuticals, Inc. Product
Table 100. Momenta Pharmaceuticals, Inc. Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020) (Million US$)
Table 101. Momenta Pharmaceuticals, Inc. Recent Development
Table 102. Mycenax Biotech Inc. Company Details
Table 103. Mycenax Biotech Inc. Business Overview
Table 104. Mycenax Biotech Inc. Product
Table 105. Mycenax Biotech Inc. Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020) (Million US$)
Table 106. Mycenax Biotech Inc. Recent Development
Table 107. Novartis AG Company Details
Table 108. Novartis AG Business Overview
Table 109. Novartis AG Product
Table 110. Novartis AG Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020) (Million US$)
Table 111. Novartis AG Recent Development
Table 112. Oncobiologics, Inc. Business Overview
Table 113. Oncobiologics, Inc. Product
Table 114. Oncobiologics, Inc. Company Details
Table 115. Oncobiologics, Inc. Revenue in Systemic Idiopathic Juvenile Arthritis Treatment Business (2015-2020) (Million US$)
Table 116. Oncobiologics, Inc. Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Type: 2020 VS 2026
Figure 2. Adalimumab Biosimilar Features
Figure 3. Canakinumab Features
Figure 4. Golimumab Features
Figure 5. Tocilizumab Biosimilar Features
Figure 6. Others Features
Figure 7. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Application: 2020 VS 2026
Figure 8. Clinic Case Studies
Figure 9. Hospital Case Studies
Figure 10. Others Case Studies
Figure 11. Systemic Idiopathic Juvenile Arthritis Treatment Report Years Considered
Figure 12. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Players in 2019
Figure 17. Global Top Systemic Idiopathic Juvenile Arthritis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Systemic Idiopathic Juvenile Arthritis Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Systemic Idiopathic Juvenile Arthritis Treatment Revenue in 2019
Figure 19. North America Systemic Idiopathic Juvenile Arthritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Systemic Idiopathic Juvenile Arthritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Systemic Idiopathic Juvenile Arthritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Systemic Idiopathic Juvenile Arthritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Systemic Idiopathic Juvenile Arthritis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed

---